Apollo Cancer Centres Introduces Innovative Multi-Cancer Test

Apollo Cancer Centres (ACC) in Chennai has officially launched a new blood-based multi-cancer detection test and announced a collaboration with Zydus Lifesciences for its implementation. The technology was developed by Guardant Health and unveiled at an event held on Friday.

The Shield™ Multi-Cancer Detection (MCD) test employs a methylation-based analysis to identify signals related to several types of cancer. This includes cancers of the bladder, colorectal region, breast, prostate, oesophagus, stomach, liver, lung, ovaries, and pancreas. The test is primarily aimed at individuals aged 45 and older who are considered to be at average risk for cancer.

In light of the increasing cancer incidence in India, Apollo Hospitals has emphasised the significance of this test. The unveiling ceremony featured key figures, including Harshad Reddy, director of group oncology at Apollo Hospitals, Simranjit Singh, chief executive officer of Guardant Health for the Asia, Middle East, and Africa (AMEA) region, and Keyur Parekh, president of BU Biologics and corporate strategy at Zydus Lifesciences.

Harit K. Chaturvedi, chief executive officer and clinical head of oncology at Apollo Hospitals, highlighted that while the test is simple to administer and shows strong sensitivity and specificity for certain cancers, it is crucial to note that no single screening method currently exists that can provide comprehensive early detection for all cancers. He recommended that the test should be conducted under the guidance of a qualified medical professional.

Simranjit Singh added that this blood test simplifies the process of identifying cancer signals through a single blood draw, thereby aiding in earlier clinical evaluations.

According to a press release issued by the companies, the Shield MCD test has attained the Breakthrough Device Designation from the U.S. Food and Drug Administration for eight different cancer types. However, it's important to clarify that this designation does not indicate FDA approval or clearance. The Shield MCD test is classified as a laboratory-developed test intended for international markets and is not currently approved for sale or use within the United States.